Neuphoria Therapeutics Inc.
NEUP
$4.84
-$0.11-2.22%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -8.62% | 173.72% | |||
| Gross Profit | 43.48% | -175.13% | |||
| SG&A Expenses | 57.74% | -23.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.80% | -16.37% | |||
| Operating Income | 4.78% | 17.31% | |||
| Income Before Tax | -106.16% | 64.34% | |||
| Income Tax Expenses | 108.77% | -1,532.10% | |||
| Earnings from Continuing Operations | -141.46% | 69.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -141.46% | 69.27% | |||
| EBIT | 4.78% | 17.31% | |||
| EBITDA | 5.02% | 19.06% | |||
| EPS Basic | -411,133.33% | 78.57% | |||
| Normalized Basic EPS | -383,100.00% | 83.33% | |||
| EPS Diluted | -411,133.33% | 78.57% | |||
| Normalized Diluted EPS | -383,100.00% | 83.33% | |||
| Average Basic Shares Outstanding | -99.94% | 48.77% | |||
| Average Diluted Shares Outstanding | -99.94% | 48.77% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
